ImmuCell Corp ICCC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ICCC is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $4.64
- Day Range
- $4.50–4.65
- 52-Week Range
- $4.26–7.76
- Bid/Ask
- $4.45 / $7.21
- Market Cap
- $35.19 Mil
- Volume/Avg
- 5,851 / 15,641
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.16
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The firm has developed products that provide immediate immunity to newborn dairy and beef cattle and is developing product line extensions of its existing products that address mastitis. Its lead product, First Defense, is manufactured to prevent scours in newborn calves. It has two segments Scours and Mastitis. The company generates the majority of its revenue from the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 77
- Website
- https://www.immucell.com
Valuation
|
Metric
|
ICCC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.35 |
Price/Sales | 2.16 |
Price/Cash Flow | — |
Price/Earnings
ICCC
Financial Strength
|
Metric
|
ICCC
|
|---|---|
Quick Ratio | 1.20 |
Current Ratio | 3.59 |
Interest Coverage | −15.01 |
Quick Ratio
ICCC
Profitability
|
Metric
|
ICCC
|
|---|---|
Return on Assets (Normalized) | −14.17% |
Return on Equity (Normalized) | −22.03% |
Return on Invested Capital (Normalized) | −14.31% |
Return on Assets
ICCC
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rjv | $456.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rczkf | $91.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jnftxfz | $89.8 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Sbkgv | $40.2 Bil | |
MRNA
| Moderna Inc | Rpc | $29.6 Bil | |
ARGX
| argenx SE ADR | Ftryf | $26.4 Bil | |
BNTX
| BioNTech SE ADR | Qvps | $23.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Wgbjm | $21.1 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xsntjxt | $17.2 Bil | |
INCY
| Incyte Corp | Jbbwdzw | $12.2 Bil |